TAK-700 8 antagonist 31)/b22-16+

31)/b22-16+

58 μM on HCT116 cells

24 hours) enhances cisplatin-induced apoptosis by activating the ROS-AMPK signaling pathway

4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21

TAK-700 8 antagonist 31)/b22-16+TAK 700, is an orally bioavailable non steroidal androgen synthesis inhibitor of steroid 17alpha monooxygenase (17, 20 lyase) with potential antiandrogen activity. TAK 700 binds to and inhibits the steroid 17alpha monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen dependent growth signaling and may inhibit cell proliferation of androgen dependent tumor cells. Product information CAS